
- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
Dendreon (DNDN) faces competition from other large companies such as Johnson/Johnson – here is an interesting contrarian article about the progress of J&J's Zytiga …. http://seekingalpha.com/article/642161-asco-data-…
The overall conclusion from this catfight is that cancer vaccine will be a focus area. I've no doubt that this will eventually mean that Dandrit will be swallowed by one of the major players.
Based on the fact that Dendreon seems to have most to gain by keeping cometitors out of the market taht they see as theirs (being first movers) I see clear advantages for Dendreon by aquiring Dandrit